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Abstract
Recent advances in animal models of glioma have facilitated a better understanding of biological
mechanisms underlying gliomagenesis and glioma progression. The limitations of existing therapy,
including surgery, chemotherapy, and radiotherapy, have prompted numerous investigators to
search for new therapeutic approaches to improve quantity and quality of survival from these
aggressive lesions. One of these approaches involves triggering a tumor specific immune response.
However, a difficulty in this approach is the the scarcity of animal models of primary CNS
neoplasms which faithfully recapitulate these tumors and their interaction with the host's immune
system. In this article, we review the existing methods utilized to date for modeling gliomas in
rodents, with a focus on the known as well as potential immunological aspects of these models. As
this review demonstrates, many of these models have inherent immune system limitations, and the
impact of these limitations on studies on the influence of pre-clinical therapeutics testing warrants
further attention.
The Potential Promise of Immunotherapy for 
Primary Brain Tumors
Primary central nervous system (CNS) malignancies,
though of low incidence in relation to many adult solid
tumors, represent a disproportionately large fraction of
cancer deaths due to their highly aggressive and fatal char-
acter. For example, Glioblastoma Multiforme (GBM), the
most common and malignant brain tumor of adults, car-
ries a median survival of less than 1 year. While current
approaches to brain tumor therapy, including surgical
resection, radiotherapy, and either systemic or local chem-
otherapy with either nitrosoureas or temozolamide,
appear to prolong survival for patients with CNS cancers,
the modest effect of these therapies, and their associated
morbidity, has left investigators in search of alternative
and novel treatments to extend quantity and quality of life
for affected patients [1].
The nearly infinite flexibility and remarkable cellular spe-
cificity of the human immune response makes immune
based approaches an attractive option to current therapy,
which either crudely target entire regions of the brain (e.g.
surgery, radiation), or potentially interfere with the cellu-
lar metabolism of all dividing cells in the body (e.g.
alkylating agents). However, immunotherapy is not with-
out technical barriers, which have hindered its incorpora-
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tion into the therapeutic arsenal for treating CNS tumors.
One such barrier is the known paucity of surface antigens
unique to glioma cells, against which an immune
response could be mounted. Another is the significant
degree of local and systemic immunosuppression known
to occur in glioma patients.
Perhaps the most significant hurdle to translating immu-
notherapeutic concepts into effective treatments for pri-
mary brain tumor patients is the fact that animals
generally do not spontaneously develop CNS neoplasms,
and, consequently, pre-clinical studies rely on artificial
systems for basing conclusions regarding approaches
being considered for use in patients. It is crucial that
tumors artificially created in animal hosts for the purpose
of developing immune based therapies, faithfully recapit-
ulate the antigenic and immunological reality that exists
in brain tumor patients. Artefactual inaccuracies could
falsely suggest the efficacy of ineffective treatments [2], or
worse, lead investigators to disregard effective ones. Given
the limitations of the existing artificial systems used in
pre-clinical studies, a critical evaluation of immunological
considerations associated with the approaches used to cre-
ate brain tumors in animals is essential prior to using
these models to evaluate immune based therapies.
Observed and Anticipated Immunological 
Deficiencies in Various Brain Tumor Models
While there exist a multitude of methods for introducing
glial-type neoplasms into the rodent CNS, which histolog-
ically mimic human primary tumors, these methods can
be described as belonging to one of two groups: 1)
Tumors created by methods which do not target a specific
gene, and 2) Tumors created by targeted mutation of
genes known to be mutated in human tumors (i.e. gene
specific methods) [3].
Non-Specific Methods
It has been known since the 1970's that repetitive intrave-
nous administration of nitrosourea compounds such as
methynitrosourea (MNU) and N-ethyl-N-nitrosourea
(ENU) produces glial-type neoplasms in immunocompe-
tent rats [4]. However, the long time required to induce
neoplasms, and inconsistency of tumor development, led
to a shift towards implantation of neoplastic cells propa-
gated in vitro [4].
While the majority of these models involve the use of
rodent glioma cells injected in syngeneic hosts, it is also
possible to use human glioma cells in vivo via their
implantation in athymic mice. The pan-immune altera-
tions seen in these rodents obviously limits the use of the
xenograft models in some immunologic investigations,
namely studies involving T-cell related immunity. These
models however do maintain some aspects of their native
immune systems and thus can be used to study some
aspects of innate immunity [5], cytokine function [6], and
natural killer cell function [7].
While rodent tumor cells implanted in rodent hosts have
been widely used to study the interaction of brain tumors
and the immune system, a number of major concerns
with this approach have been reported. The first is these
methods' dependence on cell culture for the production
of neoplastic cells to implant. For example, we have
shown that glioma cells long removed from their native
histological milleu are immunologically different than
similar cells immediately ex vivo, including changes in
MHC and FasL expression and cytokine production;
changes which apparently begin as soon as the first pas-
sage  in vitro [8]. Consistent with these observations,
expression profiling of patient tumors vs. corresponding
cell cultures have revealed widespread changes gene
expression once a tumor is subjected to in vitro growth
conditions [9].
As well, while many of these models involve implantation
of cells into animals derived from the cell-line originating
strain, these cells still represent a graft, and unfortunately
too often behave immunologically like foreign cells. Most
syngeneic graft based models of brain tumors have been
shown to induce an immunological response against
implanted tumor cells [4]. For example, one of the origi-
nal implantation models, the 9L Gliosarcoma model, was
initially created in Fischer rats using serial MNU injections
[10], and has been widely used to evaluate various immu-
notherapic therapies [11-15]. However, investigations
have demonstrated the 9L model is relatively immuno-
genic, and that it is possible to immunize animals against
these tumors using irradiated 9L cells, implying that they
are viewed as foreign tissue [16]. We have demonstrated
the occurrence of a similar phenomenon in the C6 glioma
cell line, as rats subjected to simultaneous intracerebral
and subcutaneous glioma cell implantation experienced a
nearly 9 fold improvement in survival compared to those
subjected to intracerebral implantation alone [2]. As well
the 9L Fischer model has been demonstrated to induce a
similar immune response. Other models such as CNS-1
cell implantation in Lewis rats have been found to induce
less of an immune response [4]. Thus, variability in
immune response occurs in a number of these models,
and this should be taken into consideration when evalu-
ating immunotherapies in these models.
There are significantly fewer syngeneic graft models in
mice. GL261 is murine cell line which seems to be immu-
nologically tolerated when implanted in C57BL/6 mice,
and this model had been used in some immunological
models with some success [17]. Similar to human tumors,
GL261 cells have a relatively high fraction of CD133+ gli-Journal of Translational Medicine 2009, 7:84 http://www.translational-medicine.com/content/7/1/84
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oma cells [18], which are a candidate for the "brain tumor
stem cell [18-20]." This cell population has been shown to
be relatively non-immunogenic [21], and thus these
tumors may model the human condition fairly reliably
[21]. The intact T-cell responses in these immunocompe-
tent mice make this model an improvement over
xenograft models for studying immunotherapy. The much
broader range of reagents, and the much smaller size of
mice make testing therapies in mice much easier than in
rats, thus giving GL261 model a logistical advantage over
other grafting models. Regardless, the implantation meth-
ods all suffer from the necessity to introduce foreign tissue
into mice to create brain tumors, which likely will always
have some immunologic effects.
Gene Targeted Methods
Mutational analyses of tissue from human brain tumors
have revealed that various histopathological categories for
primary CNS neoplasia generally result from a limited
number of mutation patterns. Recently, transgenic tech-
nology has allowed investigators to alter the function of
specific genes of interest and thus exploit defined genetic
lesions to produce more biologically correct models of
CNS cancers that result from activation and/or inactiva-
tion of endogenous genes in rodent genomes. A brief
summary of presently described models can be found in
table 1.
While to the genetically modified mouse models are
intended to more faithfully recapitulate human brain can-
cer in animals, little attention has been directed toward
the potential flaws in the transgenic paradigm. Many of
the genetic mutations required to produce a de novo
murine brain tumor, simultaneously interfere with genes
involved in a variety of critical immunologic functions.
Specific to the current discussion of the immune system,
Table 1: A summary of existing animal models of brain tumors
Tumorigenesis Method Technique Tumor Animal Ref
Implantation 9 L Gliosarcoma Syngeneic Graft GS Rat [17]
C6 Syngeneic Graft GBM Rat [2]
T9 Syngeneic Graft GS Rat [4]
RG2 Syngeneic Graft GBM Rat [4]
F98 Syngeneic Graft GBM Rat [4]
RT-2 Syngeneic Graft GBM Rat [4]
CNS-1 Syngeneic Graft GBM Rat [18]
GL261 Syngeneic Graft GBM Mouse [23]
Human Tumor Cells (U87, U251) Xenograft GBM Mouse [5]
Genetic p53 +/-, NF-1 +/- Germline mutations Astro Mouse [24]
GFAP- p53 +/-, NF-1 +/- Conditional KO Astro Mouse [78]
GFAP- p53 +/-, NF-1 +/-, PTEN-/- Conditional KO Astro Mouse [78]
GFAP- p53 +/-, PTEN-/- Conditional KO Astro Mouse [87]
INK4a/ARF -/-, PDGF Overexpression Germline mutation, RCAS Astro Mouse [47]
INK4a/ARF -/-, EGF-R overexpression Germline mutation, RCAS Astro Mouse [48]
INK4a/ARF -/-, Ras, Akt overexpression Germline mutation, RCAS Astro Mouse [49]
Ras, Akt overexpression RCAS Astro Mouse [80]
Ras, Akt overexpression, PTEN -/- RCAS, Conditional KO Astro Mouse [80]
GFAP-V12 Ras, EGFRvIII Astrocyte targeted mutation, Adenovirus Astro Mouse [77]
GFAP-V12 Ras, PTEN -/- Astrocyte targeted mutation, Germline mutation Astro Mouse [56]
RAS, EGF-R targeted overexpression Astrocyte targeted mutations Astro Mouse [73]
PDGF-B overexpression MMLV retrovirus ODG Mouse [75]
PDGF-B overexpression RCAS ODG Mouse [76]
Rb inactivation, PTEN -/- GFAP-Cre targeted conditional KO ODG [82]
INK4a/ARF -/-, PDGF overexp., PTEN -/- Germline mutation, RCAS, Conditional KO ODG Mouse [88]
P53 +/-, S100β promoter driven-v-erbB Germline mutation, Oligodendrocyte mutation ODG Mouse [26]
INK4a-ARF +/-, S100β promoter v-erbB Germline mutation, Oligodendrocyte mutation ODG Mouse [26]
p53 +/-, EGF-R overexpression Germline mutation, Oligodendrocyte mutation ODG Mouse [48]
Ptc +/- Germline mutation or Conditional KO MB Mouse [25]
Ptc +/-, p53 -/- Germline mutations MB Mouse [25]
Shh, n-Myc RCAS MB Mouse [89]
Rb +/-, p53 +/- GFAP-conditional KO MB Mouse [84]
BRCA2 -/-, p53 +/- Nestin-conditional KO MB Mouse [86]
Xrcc4 -/-, p53 -/- Nestin-conditional KO MB Mouse [81]
SmoM2 GFAP-conditional KO MB Mouse [79]
(abbreviations (GS-Gliosarcoma, GBM-glioblastoma multiforme, Astro-astrocytoma, ODG-oligodendroglioma, MB-Medulloblastoma, KO-
knockout)Journal of Translational Medicine 2009, 7:84 http://www.translational-medicine.com/content/7/1/84
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is the observation that processes such as lymphopoesis,
the clonal expansion of activated lymphocytes, and the
ability of leukocytes to respond to cytokines, rely on the
proper functioning of the genes that have been modified
in developing transgenic mouse models. This is especially
problematic for approaches that involve inducing gliom-
agenesis by mutating the germ line, and in so doing pro-
duce an immunologically flawed paradigm with limited
value for pre-clinical testing immunotherapies.
p53
The tumor suppressor p53 is a critical regulator of DNA
repair, cell cycle regulation, and apoptosis, and is fre-
quently mutated in human cancers, including a signifi-
cant fraction of secondary GBM. A large number of
currently described murine models utilize genetic inacti-
vation of p53 to produce brain tumors. In general, such
inhibition is achieved via either germ line p53 deletions,
or by functional p53 inhibition utilizing transforming
viral proteins.
The germ line approach has been utilized to produce a
variety of CNS tumors in mice. For example, Reilly and
colleagues found that GBM like lesions developed sponta-
neously in mice heterozygously deficient in both p53 and
the neurofibromatosis-1 gene (nf1) [22]. Wetmore and
colleagues reported that medulloblastoma development
was accelerated in susceptible Ptc +/- mice by crossing
them with p53 -/- homozygotes [23]. Additionally, Weiss
and colleagues described a model of oligodendroglioma
produced by crossing p53 +/- mice with mice which spe-
cifically overexpress EGF-R in oligodendrocytes [24].
Given its central regulatory role in multiple cell processes,
it is not surprising that germ line loss of p53 has immuno-
logical consequence. Most striking is the very high inci-
dence of spontaneous lymphoma formation in both p53
+/- and p53 -/- mice, consistent with their Li Fraumeni-
like genotype [25]. This is likely due to the key role p53
plays in lymphocyte differentiation, as it mediates an
important checkpoint in early thymocyte development
causing arrest at the CD4-CD8 double negative stage
[26,27], regulates the proliferation of pre-B-cells [28], and
alters the patterns of expression of Fas on both precursor
and mature lymphocytes [29]. Additionally, p53-deficient
mice demonstrate impaired B-cell maturation and
reduced immunoglobulin deposition in tumors, more
rapid aging of the immune system, accumulation of mem-
ory T-cells [30], and significantly greater expression of
cytokines such as IL-4, IL-6, IL-10, IFN-α [30], osteopon-
tin, and growth/differentiation factor-15 (GDF-15) [31].
Paradoxically, loss of p53 also causes a number of proin-
flammatory changes at the cellular and organismal level
[32]. As well, a large number of immunologically impor-
tant molecules such as macrophage migration inhibitory
factor (MIF) [33], IL-6 [34], IFN-α [35], IFN-β [36], and
NF-κB [37] are known to mediate at least some of their
effects through p53. In addition, thymocytes from p53
deficient mice demonstrate increased resistance to radia-
tion induced apoptosis [38,39], and p53 deficiency alters
autoantibody levels in models of autoimmunity [40] as
well as reduces mast cell susceptibility to IFN-γ induced
apoptosis [41]. Given these observations, it seems likely
that the pan-suppression of p53 activity introduced by the
use of germ line p53 inactivation alters immune system
function in a number of significant ways in these animals,
limiting the use of these models for evaluating the effect
of anti-tumor immunotherapies. Other research groups
have shown that CNS tumors can be produced by cell-tar-
geted introduction of viral antigens that suppress p53
activity. Probably the most immunologically correct
method for accomplishing this are conditional knockout
methods (described below), although a number of other
methods exist. For example, Chiu and colleagues demon-
strated that mice possessing an SV40 T-antigen transgene
(which functionally inactivates Rb and p53), driven by
the brain specific FGF-1B promoter, develop poorly differ-
entiated tumors of the medulla and 4th ventricle which
closely resemble primitive neuroectodermal tumors
(PNET) [42]. An alternate approach, described by Krynska
and colleagues, also produced PNET-like tumors by creat-
ing mice transgenic for the early region of the CY variant
of the JC virus, which encodes a T-antigen that inhibits
both p53 and Rb. To some extent, these models represent
an improvement over germ line based models because
they limit the effects of p53 inhibition to specific cells.
However the introduction of viral antigens expressed in
tumor cells, has great potential to alter the interaction of
the immune systems with these tumors [43].
INK4a/ARF
The tumor suppressor locus INK4a/ARF encodes two
tumor suppressor genes: p16INK4a, which prevents Rb
phosphorylation by binding CDK4; and p14/p19ARF,
which prevents p53 degradation via MDM2 inhibition
[44]. Loss of function mutation of one or both gene prod-
ucts encoded by INK4a/ARF is a common mutation in
human cancer, including glioma [44], and accordingly
numerous investigators have utilized INK4a/ARF silenc-
ing mutations to create CNS neoplasms in mice. Dai and
colleagues demonstrated that oligodenrogliomas and oli-
goastrocytomas could be produced in INK4a/ARF -/- mice
by forcing glial precursor cells to overexpress PDGF, using
the RCAS system [45], which involves delivery of onco-
gene-encoding viral vectors to cells that have been engi-
neered to express receptor for RCAS virus. Using the same
system, this group has described the production high
grade gliomas by combining INK4a/ARF deletion with
astrocyte specific overexpression of EGFR [46], or Ras and
Akt [47]. The immunologic significance of a tumorJournal of Translational Medicine 2009, 7:84 http://www.translational-medicine.com/content/7/1/84
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expressing RCAS antigens has yet to be addressed, and
because all of these models share the common trait of uti-
lizing germline INK4a/Arf deletion to promote glial neo-
plasms, there are undoubtedly additional immunologic
consequences of these models that would not be encoun-
tered in patients where INK4a/Arf inactivation was lim-
ited to tumor cells only. For example, in a manner similar
to p53 deficient mice, ARF -/- mice are known to sponta-
neously develop lymphomas in the absence of other
mutations [48]. This is not surprising, given the important
role these genes play in cell cycle regulation in developing
thymocytes [49,50]. As well, p14/p19ARF plays a role in
suppressing the respiratory burst in neutrophils [51,52].
Phosphatase and Tensin Homolog (PTEN)
PTEN is a tumor suppressor gene which inhibits cell pro-
liferation and growth via suppression of the PI3-kinase
signaling pathway [53]. Loss of function mutations of
PTEN have been observed in approximately 50% of de
novo GBM patients [54]. One significance of this observa-
tion was revealed by Xiao and colleagues who reported
that crossbreeding PTEN +/- mice with a strain containing
a GFAP driven truncated SV40 T antigen resulted in Rb,
p107, and p130 (but not p53) inhibition, and signifi-
cantly accelerated the development of GBM in the double
transgenic progeny [54]. Here again, the use of PTEN germ
line mutations is problematic for immunological studies
using this model. Similar to other tumor suppressor
genes, PTEN plays a critical role in lymphocyte develop-
ment, serving to eliminate T-cells that do not produce an
effective TCR re-arrangement [55]. Not surprisingly, PTEN
+/- mice have been demonstrated to frequently develop T-
cell lymphomas [55,56], as well as diffuse lymphoid
hyperplasia [57,58]. In addition, PTEN appears to regulate
leukocyte chemotaxis at a variety of levels, including reg-
ulation of CXCR4 expression [59], which directs actin
polymerization during chemotaxis [60]. It is unclear
whether or not T cells from these transgenic animals are
fully functional.
Epidermal Growth Factor Receptor (EGF-R)
EGF-R is a member of the ErbB tyrosine kinase receptor
family that is mutated or overexpressed in a variety of
human tumors, including approximately 30-50% of pri-
mary glioblastoma multiforme [61] and in roughly half of
oligodendrogliomas [62]. In addition to its role in neo-
plasia, EGF-R plays a pivotal role as a so called "master
switch" which modulates of a broad variety of immuno-
logical functions [63]. For example, EGF-R activation
appears to sensitize neutrophils to the effects of TNF-α,
leading to increased expression of the adhesion molecule
CD-11b, increased IL-8 production, and improved respi-
ratory burst by these "EGF-R primed" cells [64]. EGF-R
mediates chemotaxis in peripheral blood monocytes and
monocyte derived macrophages [65], and is critical for the
response of myeloid lineage cells to colony stimulating
factors [66]. EGF-R activation stimulates release of IL-8
from cultured bronchial epithelial cells [67], and is
hypothesized to play a critical role in the pathogenesis of
inflammatory lung diseases such as panbronchitis and
asthma [67,68]. EGF-R down-regulates CCL2, CCL5, and
CXCL10, and increases CXCL8 in keratinocytes which
likely propagates the pro-inflammatory state seen in
autoimmune skin disorders [69]. Finally, EGF-R is
required for cytokine dependent production of nitric
oxide by the pulmonary vasculature [70].
To date, there have been several reports demonstrating the
use of EGF-R overexpression to produce either oligoden-
roglioma or astrocytoma-like tumors in mice. Holland
and colleagues reported that virus expressing EGFRvIII (a
common mutant form of EGFR), and used to infect
INK4a-ARF null astrocytes or glial precursors (via the
RCAS system described above), produce gliomas in trans-
genic mice [46]. Weiss and colleagues demonstrated that
oligodendrogliomas reliably occur in mice doubly trans-
genic for an S100β promoter driven-v-erbB (a transform-
ing EGF-R allele), and either INK4a-ARF +/- or P53 +/-
heterozygosity [24]. Ding and colleagues have reported
the development of oligodendrogliomas and mixed oli-
goastrocytomas in mice carrying RAS and EGF-R trans-
genes driven by GFAP promoters [71]. In all three models,
the use of glial specific promoters likely minimize the sys-
temic effects of EGF-R overexpression on immune func-
tion. However the dependence of EGF-R models on the
use of cross breeding with germ line mutants, likely intro-
duces its own set of immunobiological consequences, as
discussed earlier.
Platelet Derived Growth Factor (PDGF)
PDGF is a growth factor that is expressed in many normal
tissues and mediates a variety of effects on cell growth and
differentiation via induced dimerization-activation of its
corresponding tyrosine kinase receptor, PDGF-R. Overex-
pression of both the PDGF isoform, PDGF-B, and the
receptor PDGF-R frequently occur in gliomas, suggesting
the potential role of a malfunctioning autocrine signaling
loop in the pathogenesis of some of these tumors [72].
Existing PDGF based models typically utilize approaches
that limit ligand overexpression to the peritumoral region,
or at least the CNS. For example, Hesselager and col-
leagues found that using a MMLV retroviral construct to
drive PDGF-B expression it was possible to induce gliom-
agenesis in neonatal mice brains, and in the absence of
other mutations (though additional relevant mutations
appeared to accelerate tumor growth) [73]. Dai and col-
leagues have demonstrated that oligodendrogliomas
could be produced solely by introduction of PDGF-BJournal of Translational Medicine 2009, 7:84 http://www.translational-medicine.com/content/7/1/84
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overexpression using the RCAS system, and that this proc-
ess was accelerated by the addition of INK4a/ARF p53
germline mutations [74].
While both models have the desirable feature of causing
gliomagenesis with minimal effects to the host immune
system, little attention has been directed towards analyz-
ing the effects of overexpression of a soluble leukocyte
chemoattractant. It is important to know whether PDGF-
driven tumors secrete similar levels of PDGF as their nat-
urally occurring counterparts, and what effect PDGF over-
expression has on local intratumoral inflammatory
responses.
Tissue Targeting with Conditional Knockouts
Tissue specific overexpression of putative oncogenes of
interest, using methods which link the gene of interest to
a glial specific promoter such as GFAP, S100β, or Nestin,
provides an appealing approach towards the creation of
spontaneously occurring brain tumors in animals that
lack the pan-immune dysfunctions seen in many germline
knockout animals [75]. Tissue targeted models involving
deletion of tumor suppressor genes is more difficult,
which is why most models to described to date have uti-
lized germline knockouts to reduce tumor suppressor
gene function. Conditional knockout models represent a
promising new attempt to eliminate tumor suppressor
function in a cell specific manner [76,77]. For brain
tumors, this involves GFAP or Nestin driven expression of
the bacteriophage protein Cre, which removes sections of
DNA between E. Coli specific DNA sequences known as
loxP domains [76]. By co-introducing Cre driven on tissue
specific promoters, and the tumor suppressor gene of
interest flanked by loxP regions, it is possible to knock out
tumor suppressor genes of interest in the cell type of
choice [76]. These techniques have recently been utilized
to create of variety of transgenic brain tumor models using
targeted conditional knockouts of p53 [78,79], PTEN
[80], Ptc [81], and Rb [82]. Frequently, conditional
knockouts used in combination with oncogenes overex-
pressed on tissue specific promoters or introduced using
viral vectors can create a localized tumor genetically simi-
lar to human cancer in an immune competent animal
[74]. While these and other similar models [83-85] cer-
tainly represent an improvement over germline mutation
based models [86], the constitutive expression of a bacte-
riophage protein in the cell of interest, raises some con-
cern regarding the immunogenicity of the tumor cells
created in this manner, and deserves future attention.
Conclusion
Animal models represent essential tools understanding
complex molecular and cellular interactions occurring in
brain tumors, and for the evaluation of potential thera-
pies. Rodents do not typically develop CNS neoplasms
spontaneously, and it is important that we understand the
physiologic changes induced by the methods used to cre-
ate thse tumors, and adjust our interpretation of results
obtained with these models accordingly. Significant
improvements have been made over the last decade to
induce gliomas using tissue targeted conditional deletions
and cell specific oncogene overexpression. While existing
models may represent improvements over chemically
induced rodent syngeneic models, the immunologic
effects of these methods are not entirely understood, and
deserve more investigation.
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